Skip to main content
TipRanks
Go Ultimate75% OFF

Ufp Technologies (UFPT) AI Stock Analysis

170 Followers
UFPT

Ufp Technologies

(NASDAQ:UFPT)

Select Model
Rating:75Outperform
Price Target:$341.00â–²(11.57% Upside)
Action:reiterated
Date:11/07/26

UFPT scores well on financial quality (strong margins, ROE, and improving leverage) and has supportive trend signals (trading above key moving averages with positive MACD). The score is held back mainly by a relatively high P/E (~30.7) and signs of growth normalization/uneven cash conversion, alongside earnings-call risks around AJR transfer delays, elevated SG&A, and a flat-to-down robotic surgery outlook for 2026.

Positive Factors
Strong profitability and MedTech growthBroad-based MedTech growth and improving gross margin indicate strong demand for UFPT’s engineered products and better operating execution. Continued expansion across patient-care and surgical markets can support durable revenue growth while the higher-margin mix strengthens earnings capacity.
Negative Factors
Growth is normalizingThe recent slowdown after several years of strong expansion suggests UFPT may be entering a more mature phase of its growth cycle. Lower top-line momentum could reduce operating leverage, constrain earnings acceleration, and make future growth more dependent on acquisitions or successful program ramps.

Ufp Technologies Key Performance Indicators (KPIs)

Net Sales by MarketRevenue distribution across the company’s end markets (for example, food, medical, industrial). Reveals where UFP Technologies gets its sales, how exposed it is to particular industries or economic cycles, and whether growth or weakness is concentrated in a few markets — key for assessing demand risk and upside potential from market diversification.

$0.00$50.00M$100.00M$150.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Medical has become the clear growth engine, with a step-up in scale followed by sustained expansion, while Non-Medical remains materially smaller and has not regained its earlier momentum. The latest acceleration supports management’s view of broad-based MedTech demand, including launch programs and capacity additions, though the expected normalization toward 6–9% organic growth suggests investors should not extrapolate the recent surge. Robotic-surgery program ramps provide an additional medium-term catalyst for the Medical market.

Data provided by:The Fly

Ufp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%50%60%UFPT+38.94%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.37B
Dividend Yield
―
Average Volume (3M)
112.04K
Price to Earnings (P/E)
30.9
Beta (1Y)
0.99
Revenue Growth
8.62%
EPS Growth
13.50%
Country
US
Employees
4,846
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Ufp Technologies Business Overview & Revenue Model

Company Description

UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated t...

How the Company Makes Money

UFPT makes money primarily by manufacturing and selling custom-engineered products and components to customers, with its largest revenue stream coming from medical device-related programs. Revenue is generally generated through (1) long-term or progr...

Ufp Technologies Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:9.04%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by double-digit sales and MedTech growth, higher gross margins and adjusted earnings, strong operating cash flow, broad customer demand, capacity investments and an active acquisition pipeline. The main challenges were delayed AJR transfers, continued AJR margin headwinds, higher SG&A and a flat-to-down 2026 outlook for robotic surgery, along with expected seasonal softness in the fourth quarter.

Positive Updates

Strong Third-Quarter Sales and Organic Growth
Third-quarter sales were $172.4 million, up 11.6%, with organic growth of 11.1%. Growth was fueled by strength in the patient beds and handling, cardiovascular, infection control and orthopedic submarkets.

Negative Updates

AJR Transfers Behind Schedule
UFP said it is behind schedule moving AJR activity to the Dominican Republic. High-labor products remain subject to customer qualification, and management expects additional transfer activity to be completed in 2027.

Company Guidance

Management does not give quarterly or annual guidance, but remains comfortable with the organic growth range of 6% to 9% and the overall 12% to 18% with regard to organic and inorganic growth combined; 2026 is a flat to down year in robotic surgery, Q4 is traditionally softer, DAS Medical is adding capacity ahead of anticipated double-digit growth next year, and additional AJR transfer activity is expected in '27. Management is comfortable in the gross-margin range of 28% to 31% and is settling in at that 29%, expects SG&A investments to moderate as the business grows, and can borrow at 3.25x EBITDA under its current credit facility.

Ufp Technologies Financial Statement Overview

Summary

Strong overall fundamentals: high profitability with healthy gross (~29%), operating (~15%) and net (~12%) margins, solid ROE (mid-to-high teens), and improving leverage (TTM debt-to-equity ~0.20). The main offsets are slowing top-line momentum in the latest TTM period and slightly weaker/uneven cash conversion (TTM operating cash flow below net income and down vs. 2025), which reduces confidence in near-term acceleration.

Income Statement

86Very Positive

Balance Sheet

84Very Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue649.51M602.80M504.42M400.07M353.79M206.32M
Gross Profit188.01M170.41M146.69M112.22M90.26M51.11M
EBITDA115.36M111.47M95.80M68.95M67.37M29.65M
Net Income76.53M68.31M58.98M44.92M41.79M15.89M
Balance Sheet
Total Assets682.63M655.08M629.00M404.14M378.19M334.13M
Cash, Cash Equivalents and Short-Term Investments20.63M20.30M13.45M5.26M4.45M11.12M
Total Debt116.54M154.48M206.03M46.04M68.37M84.36M
Total Liabilities196.92M231.20M286.24M118.05M140.65M139.69M
Stockholders Equity485.71M423.88M342.76M286.09M237.54M194.45M
Cash Flow
Free Cash Flow63.51M78.98M56.94M30.84M3.96M8.90M
Operating Cash Flow74.20M91.91M66.59M41.33M17.74M14.29M
Investing Cash Flow-17.52M-27.60M-210.16M-10.49M1.29M-101.46M
Financing Cash Flow-53.93M-58.16M152.39M-30.02M-25.89M74.05M

Ufp Technologies Technical Analysis

Technical Analysis SentimentPositive
Last Price305.65

Price Trends

50DMA294.01Positive
100DMA287.22Positive
200DMA252.41Positive

Market Momentum

MACD3.09Positive
RSI53.04Neutral
STOCH25.01Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Positive. The current price of 305.65 is above the 20-day moving average (MA) of 300.00, above the 50-day MA of 294.01, and above the 200-day MA of 252.41, indicating a bullish trend. The MACD of 3.09 indicates Positive momentum. The RSI at 53.04 is Neutral, neither overbought nor oversold. The STOCH value of 25.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UFPT.

Ufp Technologies Risk Analysis

Ufp Technologies disclosed 35 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Macro & Political - Risks related to catastrophic events or geopolitical conditions that may disrupt the company’s business

Latest Risks Added

3 New Risks
1.The conflict between the United States, Israel, and Iran and related geopolitical instability may adversely affect our business and results of operations.Q1, 2026
2.We have significant indebtedness that could adversely affect our operations, financial condition, and cash flows if we fail to meet certain financial covenants required by our debt agreements or if our access to capital markets is interrupted.Q4, 2025
3.We experienced a material information technology ("IT") systems incident in February 2026, which could result in a number of potentially unknown outcomes, including but not limited to, litigation, regulatory investigations or enforcement actions, or reputational harm, any of which could have a material impact on our business operations, financial condition, or results of operations.Q4, 2025

Ufp Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

UFPT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UFPTUFPT75Outperform$2.30B30.8716.90%―8.62%13.50%
ITGRITGR64Neutral$4.31B42.236.02%―-0.33%20.67%
CNMDCNMD63Neutral$1.43B19.847.07%―1.93%16.93%
NSYSNSYS63Neutral$32.84M17.695.14%―9.04%―
VREXVREX57Neutral$770.71M34.574.60%―5.31%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IARTIART43Neutral$1.05B82.601.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

0%50%100%150%UFPTCNMDITGRIARTNSYSVREXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
UFPT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
UFPTUfp Technologies305.6595.8045.65%
CNMDConmed Corporation48.017.3818.16%
ITGRInteger Holdings126.7058.5785.97%
IARTIntegra Lifesciences13.862.8125.43%
NSYSNortech11.464.6568.28%
VREXVarex Imaging Corporation18.157.8676.38%

Ufp Technologies Corporate Events

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance

UFP Technologies Updates Investor Presentation and Strategic Outlook

Neutral
Aug 24, 2026

In August 2026, UFP Technologies released updated investor presentation materials outlining its business activities and strategic focus for use in meetings with investors and other audiences. The presentation emphasizes the company’s role in multiple...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026